Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

    0
    215
    Reading Time: 4 minutes

    Case broadcast live to thousands of EuroPCR attendees from Clinique
    Pasteur in France

    WALTHAM, Mass.–(BUSINESS WIRE)–Corindus
    Vascular Robotics, Inc.
    (“Corindus” or the “Company”) (NYSE
    American: CVRS), a leading developer of precision vascular robotics,
    announced today its CorPath® GRX System was successfully used to perform
    a live complex robotic-assisted percutaneous coronary intervention (PCI)
    at the EuroPCR
    2019
    Conference in Paris, France on Wednesday, May 22, 2019.

    Interventional Cardiologist, PCR Vice-Chairman, and Course Director of
    EuroPCR, Dr. Jean Fajadet performed the procedure from Clinique
    Pasteur
    in Toulouse, France. It was broadcast live to EuroPCR
    attendees, marking the first time a robotic procedure using CorPath GRX
    was performed and broadcast live in Europe. Dr. Fajadet is the
    co-director of the interventional cardiology unit at Clinique Pasteur,
    which became the first site in Europe to adopt the Company’s most
    advanced vascular robotic technology when it installed the CorPath GRX
    System this year.

    “As robotic capabilities continue to advance, we are very pleased to
    share the latest developments in CorPath GRX with the attendees at
    EuroPCR,” said Mark Toland, President and Chief Executive Officer of
    Corindus. “Dr. Fajadet is a pioneer of this technology in Europe and
    understands our ultimate vision of enhancing patient care through the
    advancement of our technology. In just a few short months, he has
    established his facility as a leader in vascular robotics and has
    demonstrated the positive impact of a high-tech care model to the
    clinical community in Europe.”

    The CorPath System is the world’s only U.S. Food and Drug Administration
    (FDA) cleared and CE marked robotic platform for percutaneous coronary
    intervention (PCI) and peripheral vascular intervention (PVI)
    procedures. CorPath GRX received CE mark for neurovascular intervention
    in April 2019, broadening the application of the CorPath GRX System to
    treat all vascular beds in Europe.

    “CorPath GRX offers the level of precision and control necessary to
    perform even the most complex PCI procedures,” said Dr. Fajadet. “The
    live case went exactly as planned. I was able to complete the procedure
    with control of all interventional devices and imaging equipment from
    the control room, providing my patient with high-quality care while
    protecting myself and the cath lab team. I am pleased to share this
    technology with my peers to demonstrate how far it has come, and the
    promising future it may provide patients.”

    EuroPCR, which is the annual meeting of the European Association of
    Percutaneous Cardiovascular Interventions, is celebrating its 30th
    anniversary and will host more than 11,000 participants from across the
    globe. For attendees interested in an exclusive opportunity to gain
    firsthand experience with the latest smart procedural automation
    technology available on the CorPath GRX System, register here
    and visit Corindus at booth M49 through Friday, May 24, 2019.

    About Corindus Vascular Robotics, Inc.

    Corindus Vascular Robotics is a global technology leader in
    robotic-assisted vascular interventions. The Company’s CorPath® platform
    is the first FDA-cleared medical device to bring robotic precision to
    percutaneous coronary and vascular procedures. CorPath GRX is the second
    generation robotic-assisted technology offering enhancements to the
    platform by adding important key upgrades that increase precision,
    improve workflow, and extend the capabilities and range of procedures
    that can be performed robotically. We are focused on developing
    innovative robotic solutions to revolutionize treatment of emergent
    conditions by providing specialized and timely medical care to patients
    around the world. For additional information, visit www.corindus.com,
    and follow @CorindusInc.

    Forward Looking Statements

    Statements made in this release that are not statements of historical or
    current facts are “forward-looking statements” within the meaning of the
    Private Securities Litigation Reform Act of 1995. Forward-looking
    statements may involve known and unknown risks, uncertainties and other
    factors that may cause the actual results, performance or achievements
    of Corindus to be materially different from historical results or from
    any future results or projections expressed or implied by such
    forward-looking statements. Accordingly, readers should not place undue
    reliance on any forward-looking statements. In addition to statements
    that explicitly describe such risks and uncertainties, readers are urged
    to consider statements in the conditional or future tenses or that
    includes terms such as “believes,” “belief,” “expects,” “estimates,”
    “intends,” “anticipates” or “plans” to be uncertain and forward-looking.
    Forward-looking statements may include comments as to Corindus’ beliefs
    and expectations as to future events and trends affecting its business
    and are necessarily subject to uncertainties, many of which are outside
    Corindus’ control.

    Examples of such statements include statements regarding or such as:

    • Our ultimate vision of enhancing patient care through the advancement
      of our technology; and
    • The participants expected at the European Association of Percutaneous
      Cardiovascular Interventions.

    Important factors that could cause actual results to differ materially
    from those indicated by such forward-looking statements are described in
    the sections titled “Risk Factors” in the Company’s filings with the
    Securities and Exchange Commission, including its most recent Annual
    Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as
    reports on Form 8-K, including, but not limited to the following: our
    ability to expand our technology platform and achieve the advances
    necessary for telestenting and remote procedures, including in humans;
    our ability to expand our technology platform for use in other segments
    of the vascular intervention market, including neurointerventional and
    other more complex cardiac interventions; obtaining necessary regulatory
    approvals for the use on humans and marketing of our products in the
    United States and in other countries, including for stroke and other
    neurovascular interventions; the rate of adoption of our CorPath System
    and the rate of use of our cassettes; risks associated with market
    acceptance, including pricing and reimbursement; our ability to enforce
    our intellectual property rights; our need for additional funds to
    support our operations; our ability to manage expenses and cash flow;
    factors relating to engineering, regulatory, manufacturing, sales and
    customer service challenges; potential safety and regulatory issues that
    could slow or suspend our sales; and the effect of credit, financial and
    economic conditions on capital spending by our potential customers.
    Forward looking statements speak only as of the date they are made.
    Corindus undertakes no obligation to publicly update or revise any
    forward-looking statements, whether as a result of new information,
    future events or otherwise that occur after that date. More information
    is available on Corindus’ website at http://www.corindus.com.

    Contacts

    Corindus:
    Media Contact:
    Matter for Corindus
    Jessica
    Wolter
    T: 978-518-4536
    corindus@matternow.com
    www.matternow.com

    Investor
    Contact:
    Lisa Wilson
    In-Site Communications, Inc.
    T:
    917-543-9932
    ir@corindus.com